OTCMKTS:SKVI Skinvisible (SKVI) Stock Price, News & Analysis $0.18 0.00 (0.00%) As of 06/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Skinvisible Stock (OTCMKTS:SKVI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Skinvisible alerts:Sign Up Key Stats Today's Range$0.18▼$0.1850-Day Range$0.17▼$0.4252-Week Range$0.16▼$0.85VolumeN/AAverage Volume5,193 shsMarket Capitalization$952.73 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSkinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.Read More… Receive SKVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skinvisible and its competitors with MarketBeat's FREE daily newsletter. Email Address SKVI Stock News HeadlinesSkinvisible Delays 10-K Filing Due to Compilation IssuesMarch 31, 2025 | tipranks.comSkinvisible, Inc.: Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesJanuary 23, 2025 | finanznachrichten.deThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.June 17, 2025 | Brownstone Research (Ad)Skinvisible, Inc. (SKVI)November 16, 2024 | finance.yahoo.comSkinvisible, Inc.: Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal TreatmentMay 29, 2024 | finanznachrichten.deSkinvisible Submits Innovative Obesity Patent for Advanced Transdermal TreatmentMay 29, 2024 | finance.yahoo.comZHUD Zhuding International LimitedMay 15, 2024 | seekingalpha.comSkinvisible, Inc.: Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | finanznachrichten.deSee More Headlines SKVI Stock Analysis - Frequently Asked Questions How have SKVI shares performed this year? Skinvisible's stock was trading at $0.3370 at the start of the year. Since then, SKVI shares have decreased by 47.7% and is now trading at $0.1763. View the best growth stocks for 2025 here. How were Skinvisible's earnings last quarter? Skinvisible, Inc. (OTCMKTS:SKVI) posted its earnings results on Wednesday, May, 14th. The company reported ($0.05) EPS for the quarter. The company had revenue of $0.01 million for the quarter. How do I buy shares of Skinvisible? Shares of SKVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Skinvisible own? Based on aggregate information from My MarketBeat watchlists, some other companies that Skinvisible investors own include Angus Energy (ANGS), HEXO (HEXO), Bunker Hill Mining (BHLL), Blue Dolphin Energy (BDCO), American Power Group (APGI), Advanced Oxygen Technologies (AOXY) and Aeolus Pharmaceuticals (AOLS). Company Calendar Last Earnings5/14/2025Today6/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:SKVI CIK1085277 Webwww.skinvisible.com Phone(702) 433-7154Fax702-433-7192Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.38 million Net Margins-5,920.00% Pretax Margin-5,915.00% Return on EquityN/A Return on Assets-754.17% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual Sales$20 thousand Price / Sales47.64 Cash FlowN/A Price / Cash FlowN/A Book Value($1.99) per share Price / Book-0.09Miscellaneous Outstanding Shares5,404,000Free Float2,540,000Market Cap$952.73 thousand OptionableNot Optionable Beta1.63 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:SKVI) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skinvisible, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skinvisible With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.